Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.
about
The environment of regulatory T cell biology: cytokines, metabolites, and the microbiomeAntigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 DiabetesPromises and paradoxes of regulatory T cells in inflammatory bowel diseaseInstructive roles for cytokine-receptor binding parameters in determining signaling and functional potencyConcise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 DiabetesThe Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseIL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.Interleukin-7 optimizes FOXP3+CD4+ regulatory T cells reactivity to interleukin-2 by modulating CD25 expression.Therapeutic window of interleukin-2 for autoimmune diseases.Model-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children.Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation.Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD.Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes.Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells.Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy.Recent advances on cellular therapies and immune modulators for graft-versus-host disease.The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases.In Vivo Expansion of Regulatory T Cells by Low-Dose Interleukin-2 Treatment Increases Allograft Survival in Corneal Transplantation.Targeting Cytokines in GVHD Therapy.Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2.Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.Impact of Immune-Modulatory Drugs on Regulatory T Cell.Mechanistic approaches for the prevention and treatment of chronic GVHD.Hsp90 inhibition ameliorates CD4(+) T cell-mediated acute Graft versus Host disease in mice.Primary Immunodeficiency Diseases: Current and Emerging Therapeutics.Regulatory T cell dysfunction in type 1 diabetes: what's broken and how can we fix it?Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment.Toxoplasmosis encephalitis with immune-reconstitution inflammatory syndrome in an allogeneic stem cell transplant patient: a case report.A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantationIn Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines.Confounding effect of cyclosporine dosing when comparing horse and rabbit antithymocyte globulin in patients with severe aplastic anemia.Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy.Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study.
P2860
Q21131158-EEE9A6E9-D64F-4AAF-A423-351016F2B08AQ26770386-4CF14EF6-F67B-4873-B824-A45F46C21F25Q26777557-04CF37EE-A46B-484D-B77B-307A4DE51943Q27702599-C1AE48CC-C78A-4719-9964-E0CB09D5A6CDQ28071490-F557DDB0-9628-4DF4-A445-2B8AADBDF452Q28076264-510EDBE7-9325-4A7C-8A2C-49C2D80F477EQ33816022-C1AC0F2C-3D8D-4054-9AC8-4C3AAD40E668Q33870728-89FD3602-11AF-41E2-A315-989E6073BB0AQ34901832-8FBAF4BB-1AC1-435F-B322-B04A829AD276Q34982489-4D0A960D-425D-4792-8C6A-D5FBEFDE5617Q35499771-68E2BF48-9006-42DF-BFB0-19A73731299EQ35630817-723970F6-29CE-4A07-B70F-E814BFA55E3FQ35967925-8C51F0B9-A22F-42F3-8AAA-61E52424263CQ36036340-645EABD7-FC17-4247-9F97-61364D1DED88Q36547819-C67C260B-133F-4FF9-8C51-CB75EA4D0BC0Q37076418-9D2F96BB-A6F1-479E-AACE-9503804575E7Q37117633-3782DE59-9BB1-460E-B9EE-160A0B6277E9Q37155737-1EFDA37A-0539-457B-876B-B8151BE2DEA3Q37377103-8E2E51A8-F4D3-44FC-9820-DE369E4C3805Q37739485-EEAA4458-4395-4B44-B244-D9F6C19976C1Q38246755-31BB170C-E5A2-4C64-A9A5-4F17C5015A61Q38424758-101DEE19-E8BD-4C1A-BA47-B2AF253AC557Q38603719-B2A73625-C53F-445A-AC6D-DDFA5436FEACQ38640486-AA7AA08A-B049-41A9-AF18-94889EB5EEC2Q38742863-BAF22CA1-BF19-434B-8AC9-8C9698467EF8Q38807853-9C33ED39-08CB-471A-86EE-601F743A19E2Q38816505-8F21984E-C729-4FC1-9855-857BB394D3C5Q38907104-BCA57F8C-2A5D-48F6-9A3F-9D641B547CE9Q38918124-E348E7FF-D75C-4B31-B22F-C5B81DF9D57EQ39002166-E5EFA3FB-6959-4C16-82D4-CF948AB1F1BDQ39096609-93C9D6C8-F3B8-4630-BA9B-5D1C467FBB70Q40076704-20CE25E8-2B35-46EE-9C97-C482CCED705FQ40108816-0806911F-7022-4761-BD0D-9620433961E2Q40385568-1C7C533C-6882-4ACD-974B-E5902DF5E58FQ40535515-8CF29B62-CBC1-46F3-9971-32B51711AEA1Q41273685-CD2ED96B-F42F-4191-A986-36DF0C434FF9Q42509292-720A71F1-4BF0-4A77-BC67-25B53A24DB67Q42573838-A5E0188C-0277-44AF-B11F-1F66B02C4C8AQ42683573-577A4C23-27C5-45DA-9A1B-FE806BAA924BQ42968779-D3E75073-00C3-46D2-BD4A-0FFA65395211
P2860
Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ultra low-dose IL-2 for GVHD p ...... ral and antileukemic activity.
@en
Ultra low-dose IL-2 for GVHD p ...... ral and antileukemic activity.
@nl
type
label
Ultra low-dose IL-2 for GVHD p ...... ral and antileukemic activity.
@en
Ultra low-dose IL-2 for GVHD p ...... ral and antileukemic activity.
@nl
prefLabel
Ultra low-dose IL-2 for GVHD p ...... ral and antileukemic activity.
@en
Ultra low-dose IL-2 for GVHD p ...... ral and antileukemic activity.
@nl
P2093
P2860
P1476
Ultra low-dose IL-2 for GVHD p ...... iral and antileukemic activity
@en
P2093
A John Barrett
Aaron Foster
Alana A Kennedy-Nasser
Barbara Savoldo
Catherine M Bollard
George Carrum
Helen E Heslop
Jos Melenhorst
P2860
P304
P356
10.1158/1078-0432.CCR-13-3205
P407
P577
2014-02-26T00:00:00Z